NCT05546476 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 45
- group Id
- BG001
- value
- 46
- group Id
- BG002
- value
- 46
- group Id
- BG003
- value
- 50
- group Id
- BG004
- value
- 187
- units
- Participants
- groups
- description
- Part A: Participants were randomized to receive placebo matching to Ponsegromab SC Q4W up to 12 weeks (total of 3 doses). Part B: On completion of Part A, participants had the opportunity to receive open label Ponsegromab 400 mg Q4W SC for up to 1 year.
- id
- BG000
- title
- Part A: Placebo/ Part B: Ponsegromab 400 mg
- description
- Part A: Participants were randomized to receive Ponsegromab 100 mg SC Q4W up to 12 weeks (total of 3 doses). Part B: On completion of Part A, participants had the opportunity to receive open label Ponsegromab 400 mg Q4W SC for up to 1 year.
- id
- BG001
- title
- Part A: Ponsegromab 100 mg/ Part B: Ponsegromab 400 mg
- description
- Part A: Participants were randomized to receive Ponsegromab 200 mg SC Q4W up to 12 weeks (total of 3 doses). Part B: On completion of Part A, participants had the opportunity to receive open label Ponsegromab 400 mg Q4W SC for up to 1 year.
- id
- BG002
- title
- Part A: Ponsegromab 200 mg/ Part B: Ponsegromab 400 mg
- description
- Part A: Participants were randomized to receive Ponsegromab 400 mg SC Q4W up to 12 weeks (total of 3 doses). Part B: On completion of Part A, participants had the opportunity to receive open label Ponsegromab 400 mg Q4W SC for up to 1 year.
- id
- BG003
- title
- Part A: Ponsegromab 400 mg/ Part B: Ponsegromab 400 mg
- description
- Total of all reporting groups
- id
- BG004
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 11.26
- value
- 63.2
- group Id
- BG001
- spread
- 9.38
- value
- 70.1
- group Id
- BG002
- spread
- 9.61
- value
- 65.9
- group Id
- BG003
- spread
- 9.93
- value
- 66.1
- group Id
- BG004
- spread
- 10.28
- value
- 66.4
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- Years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 17
- group Id
- BG001
- value
- 19
- group Id
- BG002
- value
- 15
- group Id
- BG003
- value
- 18
- group Id
- BG004
- value
- 69
- title
- Female
- measurements
- group Id
- BG000
- value
- 28
- group Id
- BG001
- value
- 27
- group Id
- BG002
- value
- 31
- group Id
- BG003
- value
- 32
- group Id
- BG004
- value
- 118
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 5
- group Id
- BG004
- value
- 9
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 43
- group Id
- BG001
- value
- 42
- group Id
- BG002
- value
- 44
- group Id
- BG003
- value
- 43
- group Id
- BG004
- value
- 172
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 2
- group Id
- BG004
- value
- 6
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 18
- group Id
- BG001
- value
- 19
- group Id
- BG002
- value
- 18
- group Id
- BG003
- value
- 15
- group Id
- BG004
- value
- 70
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 26
- group Id
- BG001
- value
- 27
- group Id
- BG002
- value
- 28
- group Id
- BG003
- value
- 35
- group Id
- BG004
- value
- 116
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 1
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- population Description
- Safety analysis set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention. Participants were analyzed according to the study intervention they actually received.
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 45
- group Id
- BG001
- value
- 46
- group Id
- BG002
- value
- 46
- group Id
- BG003
- value
- 50
- group Id
- BG004
- value
- 187
- units
- Participants
- groups
- description
- Part A: Participants were randomized to receive placebo matching to Ponsegromab SC Q4W up to 12 weeks (total of 3 doses). Part B: On completion of Part A, participants had the opportunity to receive open label Ponsegromab 400 mg Q4W SC for up to 1 year.
- id
- BG000
- title
- Part A: Placebo/ Part B: Ponsegromab 400 mg
- description
- Part A: Participants were randomized to receive Ponsegromab 100 mg SC Q4W up to 12 weeks (total of 3 doses). Part B: On completion of Part A, participants had the opportunity to receive open label Ponsegromab 400 mg Q4W SC for up to 1 year.
- id
- BG001
- title
- Part A: Ponsegromab 100 mg/ Part B: Ponsegromab 400 mg
- description
- Part A: Participants were randomized to receive Ponsegromab 200 mg SC Q4W up to 12 weeks (total of 3 doses). Part B: On completion of Part A, participants had the opportunity to receive open label Ponsegromab 400 mg Q4W SC for up to 1 year.
- id
- BG002
- title
- Part A: Ponsegromab 200 mg/ Part B: Ponsegromab 400 mg
- description
- Part A: Participants were randomized to receive Ponsegromab 400 mg SC Q4W up to 12 weeks (total of 3 doses). Part B: On completion of Part A, participants had the opportunity to receive open label Ponsegromab 400 mg Q4W SC for up to 1 year.
- id
- BG003
- title
- Part A: Ponsegromab 400 mg/ Part B: Ponsegromab 400 mg
- description
- Total of all reporting groups
- id
- BG004
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 11.26
- value
- 63.2
- group Id
- BG001
- spread
- 9.38
- value
- 70.1
- group Id
- BG002
- spread
- 9.61
- value
- 65.9
- group Id
- BG003
- spread
- 9.93
- value
- 66.1
- group Id
- BG004
- spread
- 10.28
- value
- 66.4
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- Years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 17
- group Id
- BG001
- value
- 19
- group Id
- BG002
- value
- 15
- group Id
- BG003
- value
- 18
- group Id
- BG004
- value
- 69
- title
- Female
- measurements
- group Id
- BG000
- value
- 28
- group Id
- BG001
- value
- 27
- group Id
- BG002
- value
- 31
- group Id
- BG003
- value
- 32
- group Id
- BG004
- value
- 118
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 5
- group Id
- BG004
- value
- 9
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 43
- group Id
- BG001
- value
- 42
- group Id
- BG002
- value
- 44
- group Id
- BG003
- value
- 43
- group Id
- BG004
- value
- 172
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 2
- group Id
- BG004
- value
- 6
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 18
- group Id
- BG001
- value
- 19
- group Id
- BG002
- value
- 18
- group Id
- BG003
- value
- 15
- group Id
- BG004
- value
- 70
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 26
- group Id
- BG001
- value
- 27
- group Id
- BG002
- value
- 28
- group Id
- BG003
- value
- 35
- group Id
- BG004
- value
- 116
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 1
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- population Description
- Safety analysis set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention. Participants were analyzed according to the study intervention they actually received.
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle